Intercept Shares Fall as FDA Again Questions Risk-Benefit of NASH Treatment

Shares of Intercept Pharmaceuticals fell 27% in mid-morning trading Wednesday after FDA briefing documents noted modest benefits versus serious risks with obeticholic acid tablets.